Top

Published in:

01-11-2010 | Clinical Trial Updates and Hotline Sessions

Hotline sessions and clinical trial updates presented at the European Society of Cardiology Congress in Stockholm 2010

Authors: Matthias Lenski, Felix Mahfoud, Christian Werner, Axel Bauer, Michael Böhm

Published in: Clinical Research in Cardiology | Issue 11/2010

Abstract

This article gives an overview on several novel clinical trials in the field of cardiovascular (CV) medicine which were presented during the hotline sessions and clinical trial updates at the European Society of Cardiology Congress, held in Stockholm, Sweden, from 28th August to 1st September 2010. The data have been presented by leading experts in the accordant field with relevant positions in the trials. Unpublished reports should be considered as preliminary data as the analysis may change in the final publications. The summaries presented in the manuscript were generated from the oral presentations and should provide the readers with the most comprehensive information on diagnostic and therapeutic development in CV medicine similar as previously reported Schirmer SH et al. (Clin Res Cardiol 11:691–699, 2009).

Schirmer SH et al (2009) Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more. Clin Res Cardiol 98(11):691–699CrossRefPubMed

Swedberg K et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376(9744):875–885CrossRefPubMed

McAlister FA et al (2009) Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 150(11):784–794PubMed

Böhm M et al (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376(9744):886–894CrossRefPubMed

Voors AA et al (2010) A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J

Leonardi S et al (2010) Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J 160(1):65–72CrossRefPubMed

Goto S et al (2010) Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J

Montalescot G et al (2006) Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 355(10):1006–1017CrossRefPubMed

Schulz S et al (2010) ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. Eur Heart J

10.

Kastrati A et al (2008) Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 359(7):688–696CrossRefPubMed

11.

Wijns W et al (2010) Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J

12.

Taggart DP et al (2010) Randomized trial to compare bilateral vs. single internal mammary coronary artery bypass grafting: 1-year results of the Arterial Revascularisation Trial (ART). Eur Heart J

13.

Eikelboom JW (2010) Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 159(3):348–353 e1CrossRefPubMed

14.

Ehrlich JR, Hohnloser SH, Nattel S (2006) Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 27(5):512–518CrossRefPubMed

15.

Vermes E et al (2003) Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the studies of left ventricular dysfunction (SOLVD) trials. Circulation 107(23):2926–2931CrossRefPubMed

16.

Steg PG et al (2010) Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA

17.

Yu CM et al (2009) Biventricular pacing in patients with bradycardia and normal ejection fraction. N Engl J Med 361(22):2123–2134CrossRefPubMed

18.

Cleland JG et al (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352(15):1539–1549CrossRefPubMed

19.

Maisch B et al (2004) Guidelines on the diagnosis and management of pericardial diseases executive summary; the task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J 25(7):587–610CrossRefPubMed

20.

Finkelstein Y et al (2002) Colchicine for the prevention of postpericardiotomy syndrome. Herz 27(8):791–794CrossRefPubMed

21.

Imazio M et al (2010) COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J [Epub ahead of print]

22.

Leontyev S et al (2009) Aortic valve replacement in octogenarians: utility of risk stratification with EuroSCORE. Ann Thorac Surg 87(5):1440–1445CrossRefPubMed

Title: Hotline sessions and clinical trial updates presented at the European Society of Cardiology Congress in Stockholm 2010
Authors: Matthias Lenski
Felix Mahfoud
Christian Werner
Axel Bauer
Michael Böhm
Publication date: 01-11-2010
Publisher: Springer-Verlag
Published in: Clinical Research in Cardiology / Issue 11/2010
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-010-0238-3

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Hotline sessions and clinical trial updates presented at the European Society of Cardiology Congress in Stockholm 2010

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2010

Parasympathetic but not sympathetic cardiac dysfunction at early stages of Parkinson’s disease

Diagnosis of early myocarditis after respiratory or gastrointestinal tract viral infection: insights from cardiovascular magnetic resonance

Inappropriate shock delivery by implantable cardioverter defibrillator due to electrical leak from bathroom tap

Admission glucose level and in-hospital outcomes in diabetic and non-diabetic patients with acute myocardial infarction

Non-compaction cardiomyopathy of the left ventricle diagnosed by cardiac magnetic resonance in a 2-generation family

Catheter ablation of ventricular tachycardias in patients with ischemic cardiomyopathy: validation of voltage mapping criteria for substrate modification by myocardial viability assessment using FDG PET

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page